MX2023000034A - Hp-hmg para su uso en el tratamiento de la infertilidad en una paciente con sindrome de ovario poliquistico. - Google Patents
Hp-hmg para su uso en el tratamiento de la infertilidad en una paciente con sindrome de ovario poliquistico.Info
- Publication number
- MX2023000034A MX2023000034A MX2023000034A MX2023000034A MX2023000034A MX 2023000034 A MX2023000034 A MX 2023000034A MX 2023000034 A MX2023000034 A MX 2023000034A MX 2023000034 A MX2023000034 A MX 2023000034A MX 2023000034 A MX2023000034 A MX 2023000034A
- Authority
- MX
- Mexico
- Prior art keywords
- hmg
- infertility
- patient
- treatment
- polycystic ovary
- Prior art date
Links
- 201000010065 polycystic ovary syndrome Diseases 0.000 title abstract 2
- 208000000509 infertility Diseases 0.000 title 1
- 230000036512 infertility Effects 0.000 title 1
- 231100000535 infertility Toxicity 0.000 title 1
- 230000002611 ovarian Effects 0.000 abstract 2
- 206010002659 Anovulatory cycle Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001850 reproductive effect Effects 0.000 abstract 1
- 230000000638 stimulation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0608—Germ cells
- C12N5/0609—Oocytes, oogonia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Reproductive Health (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Gynecology & Obstetrics (AREA)
- Biotechnology (AREA)
- Pregnancy & Childbirth (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se describen composiciones y métodos de tecnología de reproducción asistida que usan menotropina altamente purificada (HP-hMG) para estimular el desarrollo de folículos, particularmente en mujeres que han sido diagnosticadas con oligoovulación y/o SOP y que se prevé que tienen una respuesta ovárica alta a la estimulación ovárica controlada.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2020/039745 WO2021262186A1 (en) | 2020-06-26 | 2020-06-26 | Hp-hmg for use in the treatment of infertility in a patient with polycystic ovary syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023000034A true MX2023000034A (es) | 2023-02-02 |
Family
ID=71662343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023000034A MX2023000034A (es) | 2020-06-26 | 2020-06-26 | Hp-hmg para su uso en el tratamiento de la infertilidad en una paciente con sindrome de ovario poliquistico. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230248807A1 (es) |
| EP (1) | EP4171612A1 (es) |
| JP (1) | JP2023534400A (es) |
| KR (1) | KR20230028368A (es) |
| CN (1) | CN116490202A (es) |
| AU (1) | AU2020454716A1 (es) |
| BR (1) | BR112022025724A2 (es) |
| CA (1) | CA3184329A1 (es) |
| CO (1) | CO2022018536A2 (es) |
| IL (1) | IL299474A (es) |
| MX (1) | MX2023000034A (es) |
| WO (1) | WO2021262186A1 (es) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3261661T3 (pl) * | 2015-02-26 | 2024-03-25 | Ferring B.V. | Menotropina do leczenia niepłodności |
-
2020
- 2020-06-26 BR BR112022025724A patent/BR112022025724A2/pt unknown
- 2020-06-26 US US18/012,753 patent/US20230248807A1/en active Pending
- 2020-06-26 MX MX2023000034A patent/MX2023000034A/es unknown
- 2020-06-26 CA CA3184329A patent/CA3184329A1/en active Pending
- 2020-06-26 IL IL299474A patent/IL299474A/en unknown
- 2020-06-26 AU AU2020454716A patent/AU2020454716A1/en active Pending
- 2020-06-26 JP JP2022580468A patent/JP2023534400A/ja active Pending
- 2020-06-26 WO PCT/US2020/039745 patent/WO2021262186A1/en active Application Filing
- 2020-06-26 CN CN202080102435.0A patent/CN116490202A/zh active Pending
- 2020-06-26 EP EP20742573.7A patent/EP4171612A1/en active Pending
- 2020-06-26 KR KR1020237001110A patent/KR20230028368A/ko unknown
-
2022
- 2022-12-21 CO CONC2022/0018536A patent/CO2022018536A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4171612A1 (en) | 2023-05-03 |
| US20230248807A1 (en) | 2023-08-10 |
| JP2023534400A (ja) | 2023-08-09 |
| CO2022018536A2 (es) | 2022-12-30 |
| IL299474A (en) | 2023-02-01 |
| BR112022025724A2 (pt) | 2023-01-03 |
| KR20230028368A (ko) | 2023-02-28 |
| CA3184329A1 (en) | 2021-12-30 |
| CN116490202A (zh) | 2023-07-25 |
| AU2020454716A1 (en) | 2023-01-19 |
| WO2021262186A1 (en) | 2021-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022010425A (es) | Metodos de tratamiento de enfermedades asociadas a los receptores de estrogenos. | |
| JOP20220179A1 (ar) | N4-هيدروكسي سيتيدين ومشتقات واستخدامات مضادة للفيروسات مرتبطة بها | |
| PH12017501493A1 (en) | Methods of treating infertility | |
| MX2022002740A (es) | Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes. | |
| ZA201903226B (en) | Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same | |
| WO2021203103A3 (en) | Ace2 receptor polymorphisms and varying susceptibility to sars-cov-2, methods for diagnosis and treatment | |
| MX2021013901A (es) | Composiciones y métodos para el tratamiento del cáncer. | |
| MX2023001296A (es) | Composiciones y metodos para tratar enfermedades y trastornos. | |
| CL2021001903A1 (es) | Tratamiento de la hepatotoxicidad | |
| BR112022003659A2 (pt) | Composições e métodos de tratamento de doenças vasculares | |
| MX2023005591A (es) | Metodos de tratamiento de enfermedades y trastornos. | |
| MX2023000034A (es) | Hp-hmg para su uso en el tratamiento de la infertilidad en una paciente con sindrome de ovario poliquistico. | |
| DE60210297D1 (de) | Verwendung von long pentraxin ptx3 für die behandlung von infertilität bei frauen | |
| CA3156499A1 (en) | CHINONE, HYDROCHINONE AND NAPHTOCHINONE ANALOGS OF VATIQUINONE FOR THE TREATMENT OF DISEASES WITH MITOCHONDRIAL DISORDERS | |
| MX2021009170A (es) | Cristal de compuesto de diariltiohidantoina. | |
| GEP20227384B (en) | Topical formulations comprising strontium and methylsulfonylmethane (msm) and methods of treatment | |
| WO2022216379A8 (en) | Combination therapies for the treatment of cancer | |
| MX2023006551A (es) | Tratamiento de las convulsiones refractarias. | |
| MX2020005223A (es) | Método para aumentar la tasa de implantación embrionaria en una paciente que padece síndrome de ovario poliquístico. | |
| CL2022003746A1 (es) | Hp-hmg para su uso en el tratamiento de la infertilidad en una paciente con síndrome | |
| CL2021000928A1 (es) | Composiciones y métodos para la estimulación ovárica controlada | |
| CL2021001172A1 (es) | Uso de tivozanib para tratar sujetos con cáncer refractario. | |
| MX2022003816A (es) | Compuestos antibacterianos. | |
| MX2022006883A (es) | Uso de isatuximab para el tratamiento del mieloma multiple recidivante y/o refractario. | |
| MX2022012404A (es) | Composiciones que comprenden 15-hepe para tratar o prevenir trastornos hematológicos y/o enfermedades relacionadas. |